Interest in Electronic Cigarettes for Smoking Cessation Among Adults With Opioid Use Disorder in Buprenorphine Treatment: A Mixed-Methods Investigation.


Journal

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
ISSN: 1469-994X
Titre abrégé: Nicotine Tob Res
Pays: England
ID NLM: 9815751

Informations de publication

Date de publication:
15 06 2022
Historique:
received: 27 07 2021
revised: 13 10 2021
accepted: 14 12 2021
pubmed: 17 12 2021
medline: 18 6 2022
entrez: 16 12 2021
Statut: ppublish

Résumé

Individuals in treatment for opioid use disorder (OUD) have high smoking rates and limited success with Food and Drug Administration (FDA)-approved cessation aids, suggesting need for novel approaches. Electronic cigarettes (e-cigarettes) might benefit this population, but e-cigarettes' acceptability for tobacco reduction or cessation among smokers in OUD treatment is not known. A cross-sectional mixed-methods study of 222 adults in OUD treatment with buprenorphine in the Boston, Massachusetts metropolitan area was conducted in 2020. We used quantitative and qualitative data to investigate individuals' experience with and interest in e-cigarettes and other methods for smoking cessation and assessed factors associated with interest in e-cigarette use. One hundred sixty (72%) of the 222 participants were past 30-day cigarette smokers. They most frequently reported having ever used nicotine replacement therapy (NRT; 83%) and e-cigarettes (71%) for smoking cessation and most often indicated interest in using NRT (71%) and e-cigarettes (44%) for future smoking cessation. In multiple logistic regression analysis, interest in using e-cigarettes for future smoking cessation was independently associated with having ever used e-cigarettes for smoking cessation, current e-cigarette use, and perceiving e-cigarettes to be less harmful than cigarettes (ps < .05). In qualitative data, many current vapers/former smokers reported that e-cigarettes had been helpful for quitting cigarettes. For current smokers who currently or formerly vaped, frequently reported challenges in switching to e-cigarettes were concerns about replacing one addiction with another and e-cigarettes not adequately substituting for cigarettes. E-cigarettes had a moderate level of acceptability for smoking cessation among cigarette smokers in OUD treatment. More research is warranted to test the efficacy of this approach. Individuals in treatment for opioid use disorder (OUD) have high smoking rates and limited success with existing smoking cessation tools, suggesting a need for novel cessation treatment approaches. In this mixed-methods study of individuals receiving medication treatment for OUD with buprenorphine in Massachusetts in 2020, we found a moderate level of acceptability of e-cigarettes for smoking cessation.

Identifiants

pubmed: 34915581
pii: 6463503
doi: 10.1093/ntr/ntab259
pmc: PMC9199932
doi:

Substances chimiques

Buprenorphine 40D3SCR4GZ

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1134-1138

Subventions

Organisme : NIDA NIH HHS
ID : K12 DA043490
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Nicotine Tob Res. 2012 Jan;14(1):75-8
pubmed: 22025545
Drug Alcohol Depend. 2020 Sep 1;214:108164
pubmed: 32652375
Cochrane Database Syst Rev. 2020 Oct 14;10:CD010216
pubmed: 33052602
Addict Behav. 2021 Aug;119:106947
pubmed: 33892312
Addiction. 2020 Mar;115(3):518-526
pubmed: 31628817
Drug Alcohol Depend. 2021 Jan 1;218:108438
pubmed: 33271434
Drug Alcohol Depend. 2019 Apr 1;197:37-41
pubmed: 30769264
Nicotine Tob Res. 2016 May;18(5):1157-62
pubmed: 26712843
J Subst Abuse Treat. 2015 May;52:73-7
pubmed: 25483740
Harv Rev Psychiatry. 2015 Mar-Apr;23(2):63-75
pubmed: 25747920
CNS Drugs. 2020 Apr;34(4):367-387
pubmed: 32107731
PLoS One. 2015 Mar 25;10(3):e0120581
pubmed: 25807109
Addict Behav. 2019 Apr;91:45-50
pubmed: 30006020
J Risk Uncertain. 2020 Jun;60(3):281-307
pubmed: 34504389
Nicotine Tob Res. 2020 Dec 15;22(Suppl 1):S96-S99
pubmed: 33320257
J Subst Abuse Treat. 2014 Aug;47(2):175-9
pubmed: 24912863

Auteurs

Joanna M Streck (JM)

Tobacco Research and Treatment Center, Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston MA, USA.
Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Susan Regan (S)

Tobacco Research and Treatment Center, Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston MA, USA.

Jordan Neil (J)

Department of Family and Preventive Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Health Promotion Research Center, Stephenson Cancer Center, Oklahoma City, OK, USA.

Sara Kalkhoran (S)

Tobacco Research and Treatment Center, Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston MA, USA.

Priya S Gupta (PS)

Tobacco Research and Treatment Center, Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston MA, USA.

Benjamin Bearnot (B)

Tobacco Research and Treatment Center, Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston MA, USA.

Faith K Coker (FK)

Tobacco Research and Treatment Center, Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston MA, USA.

Kelly M Kalagher (KM)

Tobacco Research and Treatment Center, Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston MA, USA.

Elyse R Park (ER)

Tobacco Research and Treatment Center, Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston MA, USA.
Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Sarah Wakeman (S)

Tobacco Research and Treatment Center, Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston MA, USA.

Nancy A Rigotti (NA)

Tobacco Research and Treatment Center, Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH